The most meaningful outcomes are often the ones that transform everyday life.

As we work to advance gene therapy for rare, fatal genetic conditions such as Canavan disease, it is easy to become focused on the data points and statistics that are essential for regulatory progress. Yet those numbers tell only part of the story.

What ultimately matters most are the changes that reshape daily life for children and their families. While gross motor gains are important milestones, the emergence of physical autonomy, communication, and sensory engagement can be equally profound. Sometimes progress looks like improved truncal tone, making seating and positioning safer. Sometimes it is the ability to chew and swallow more effectively, reducing the risk of aspiration. Sometimes it is a child pointing, vocalizing, or otherwise expressing a choice for the first time.

And sometimes, perhaps most beautifully, it is siblings fighting over a toy.

These are the moments that remind us why this work matters. Behind every data set is a child, a family, and a future that may be changed by the possibility of meaningful, everyday experiences that many once thought were out of reach.

These functional, quality-of-life moments are not secondary to the science; they are part of the science. These sensory and physical milestones show that targeted therapies can fundamentally expand a child’s day-to-day capability.

Regulatory Shifts: Accountability and Access at the FDA

While the most meaningful progress happens at home, something significant is shifting in the regulatory environment to help bring these therapies to families faster.

Earlier this year, the FDA initially rejected the Biologics License Application of Navsunli (clemidsogene lanparvovec), REGENXBIO’s one-time gene therapy for Hunter syndrome. The National MPS Society and patient advocates challenged the agency’s trial requirements for a disease affecting only 2,000 people worldwide.

On June 3rd, the needle moved. Advocacy leaders met directly with FDA leadership and within weeks, the agency reversed its rejection of Navsunli, agreeing that existing clinical data are sufficient to support an accelerated approval filing.

This was not an isolated event. Just one week prior, uniQure received a similar regulatory reversal. The FDA agreed that Phase 1/2 data for AMT-130, their Huntington’s disease gene therapy, would suffice for an accelerated approval filing, walking back previous demands for a sham-controlled trial design.

Two critical reversals within a single month can be traced directly back to patient advocacy that refused to accept a standstill, establishing a vital precedent for how rare disease data are evaluated.

For Myrtelle, this context matters. Our selection for the FDA’s START Pilot Program and our RMAT designation position us within the exact accelerated pathways that patient communities have now demonstrably unlocked. The regulatory system is increasingly recognizing that a different approach is required to evaluate products for rare diseases, and every functional win counts.

Actionable Advocacy: Driving the Momentum Forward

Advocacy moves when communities move together. Here is how you can take action right now:

  • Share the Precedent: The REGENXBIO and uniQure reversals are signals worth sharing with physicians, policymakers, and insurers. Every reversal strengthens the case for the next one.
  • Support the Organizations in the Room: The advocacy that moved the FDA is built by organizations that show up year after year. Champion the Cure Canavan Fund, the Canavan Foundation, and National Tay-Sachs & Allied Diseases Association (NTSAD). Donate, amplify, and stay connected.
  • Value the Specifics: The most powerful tool in rare disease advocacy is specificity. When speaking about the impact of research, highlight the physical milestones, the sensory breakthroughs, and the moments of newfound independence. These are the details that move the world.